Palliation of esophageal malignancy with photodynamic therapy.
Sixteen patients with esophageal malignancies received photodynamic therapy after 3 mg of hematoporphyrin derivative (Photofrin I) or 2 mg of Photofrin II per kilogram of body weight was injected intravenously two to six days prior to treatment. A tunable dye argon laser system delivered 630 nm light through quartz fibers passed through the biopsy channel of a gastroscope. All patients obtained improvement in swallowing, usually from total obstruction or clear liquids only to a regular diet within three weeks and with new techniques, at least liquids within three days of treatment. Karnofsky Performance Status (KPS) and esophageal grades were measured before treatment, 1 month following treatment, and periodically until death. Ten patients died an average of 3.7 months after initial treatment (range, 0.6 to 19 months). Six patients are alive at 11, 10, 5, 2.5, 2 months, and 1 month after treatment. The median survival of 12 patients treated more than 6 months ago was 6.5 months and of 9 patients with an initial KPS higher than 30, 8.1 months.
McCaughan
J S
JS
Williams
T E
TE
Bethel
B H
BH
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality; D004938:Esophageal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D017324:Hematoporphyrin Derivative; D006415:Hematoporphyrins / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D010166:Palliative Care / Q000379:methods*; D010778:Photochemotherapy / Q000009:adverse effects / Q000379:methods*; D011788:Quality of Life; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use
D006415:Hematoporphyrins; D011838:Radiation-Sensitizing Agents; D017324:Hematoporphyrin Derivative